Navigation Links
Thomson Reuters Launches Thomson Pharma KOLexperts(R) to Help the Pharmaceutical Industry Objectively Identify, Verify and Rank Scientific Experts, Product Advocates, Clinical Investigators and Key Opinion Leaders
Date:10/15/2008

PHILADELPHIA and LONDON, Oct. 15 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, announced today the launch of Thomson Pharma KOLexperts, a new solution designed to help pharmaceutical organizations identify, verify, and develop productive relationships with key opinion leaders (KOLs) and scientific experts. It is the first solution available to the industry that allows users to rank life sciences KOLs with a range of objective metrics. Designed for scientific expertise identification, Thomson Pharma KOLexperts offers a variety of tools to find experts with specific scientific competencies.

"Leveraging external experts is crucial to the success of drug development today. Our customers increasingly want to build their research, clinical and marketing teams based on objective criteria such as scientific credibility, but lack the information and analysis to do so. We have harnessed Thomson Reuter's long legacy in information aggregation, citation analysis, and scientific expertise to deliver a first-in-class solution to our customers," said Wendy Hamilton, vice president, product strategy, Pharmaceutical and Chemicals Markets, Thomson Reuters. "When designing Thomson Pharma KOLexperts, our objective was to create a life sciences 'Who's Who' of experts that can be leveraged at any point from discovery to market. We utilize trusted data that is skillfully indexed, carefully researched, and always up to date."

Users of Thomson Pharma KOLexperts can search for and view experts in a therapy area of interest, and determine a scientist's ranking at a glance as extrapolated from cited work, research activity, speaking engagements and other promotional or educational efforts. As there is no one ranking system that addresses all priorities and considerations, the customer can adjust the ranking approach directly within the product using simple point and click. The solution brings together the core databases of Thomson Reuters with key external data sources to offer an up-to-the-minute snapshot of an expert's status. It also allows users to identify the scientists recognized as leaders in their therapeutic areas and highlight new and emerging stars.

"In the face of an emerging regulatory environment that demands greater transparency into KOL selection and fair remuneration, objectively identifying KOLs based on scientific merit paves the way for success throughout the drug development and marketing process. Thomson Pharma KOLexperts is the first product to enable the optimal alignment of KOLs with the business strategies of individual life sciences organizations based on science, not subjectivity," added Hamilton.

Thomson Pharma KOLexperts can be adapted to the unique needs of each subscribing company. In addition to the standard product, new types of expert profiles can be created upon demand based on customer request.

For more information, visit: http://www.thomsonreuters.com/products_services/scientific/kolexperts

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to http://www.thomsonreuters.com


'/>"/>
SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Thomson Scientific Predicts Nobel Laureates
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
4. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
5. Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals
6. Thomson Acquires Prous Science
7. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
8. Thomson Scientific Ranks Australian Universities and Research Institutes
9. Thomson Scientific Launches Confessions ... of a User Campaign Asking Are You the New Face of Research?
10. Contract Renewal Extends Thomson Healthcares Long-Standing Relationship with University Hospitals
11. Thomson Healthcare Launches Application That Assesses Physician Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced that it will ... development program, based on its proprietary self-delivering RNAi ... (SID) 76 th Annual Meeting.  The SID ... relevant to skin health and disease through education, ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: